Glucosamine and Faslodex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Glucosamine (glucosamine) and Faslodex (fulvestrant). Common drug interactions include white blood cell count decreased among females.

The phase IV clinical study analyzes what interactions people have when they take Glucosamine and Faslodex. It is created by eHealthMe based on reports of 48 people who take the same drugs from the FDA, and is updated regularly.

What is Glucosamine?

Glucosamine has active ingredients of glucosamine. It is often used in joint pain. eHealthMe is studying from 15,547 Glucosamine users. Check the latest studies of Glucosamine.

What is Faslodex?

Faslodex has active ingredients of fulvestrant. It is often used in breast cancer metastatic. eHealthMe is studying from 19,255 Faslodex users. Check the latest studies of Faslodex.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

48 people who take Glucosamine and Faslodex together, and have interactions are studied.

Glucosamine and Faslodex drug interactions.

What are the common drug interactions of Glucosamine and Faslodex, by gender? *:

female:

White blood cell count decreased
Fatigue (feeling of tiredness)
Pain in extremity
Blood potassium increased
Flatulence (flatus expelled through the anus)
Stomatitis (inflammation of mucous membrane of mouth)
Urinary tract infection
Dyspnoea (difficult or laboured respiration)
Malaise (a feeling of general discomfort or uneasiness)
Cellulitis (infection under the skin)

male:

n/a

What are the common drug interactions of Glucosamine and Faslodex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Drug ineffective
Injection site pain
Laryngospasm (an uncontrolled/involuntary muscular contraction of larynx)
Malignant neoplasm progression (cancer tumour came back)
Metastases to bone (cancer spreads to bone)
Nerve injury
Weight increased
Abdominal pain
Abscess (pus)
Acquired oesophageal web (structural abnormalities in the oesophagus)

60+:

White blood cell count decreased
Fatigue (feeling of tiredness)
Pain in extremity
Flatulence (flatus expelled through the anus)
Urinary tract infection
Weight decreased
Dyspnoea (difficult or laboured respiration)
Full blood count decreased
Myalgia (muscle pain)
Alopecia (absence of hair from areas of the body)

What are the existing conditions these people have? *

Breast Cancer: 10 people, 20.83%
Neoplasm Malignant (cancer tumour): 8 people, 16.67%
Pain: 7 people, 14.58%
Breast Cancer Female: 6 people, 12.50%
Metastases To Bone (cancer spreads to bone): 4 people, 8.33%
Bone Disorder: 4 people, 8.33%
Thrombosis (formation of a blood clot inside a blood vessel): 3 people, 6.25%
Fungal Infection: 3 people, 6.25%
Fatigue (feeling of tiredness): 3 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Glucosamine and Faslodex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously